Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187345 | 1.00 | HSD17B10 (0.48) | HSD17B10NPC1LMNANPSR1SMN1; SMN2 | |
| SCHEMBL4590220 | 0.81 | HSD17B10 (0.54) | HSD17B10NPC1LMNANPSR1SMN1; SMN2 | |
| SCHEMBL20189166 | 0.81 | RAB9A (0.38) | HSD17B10LMNAKDM4EALDH1A1 | |
| SCHEMBL489823 | 0.78 | HSD17B10 (0.57) | HSD17B10NPC1LMNANPSR1SMN1; SMN2 | |
| SCHEMBL12519784 | 0.78 | MEN1 (0.51) | HSD17B10KMT2AMEN1USP30ALDH1A1 | |
| SCHEMBL11448325 | 0.77 | HSD17B10 (0.62) | HSD17B10NPC1LMNANPSR1SMN1; SMN2 | |
| SCHEMBL5423413 | 0.76 | HSD17B10 (0.61) | HSD17B10NPC1LMNANPSR1SMN1; SMN2 | |
| SCHEMBL4070752 | 0.76 | HSD17B10 (0.61) | HSD17B10NPC1LMNANPSR1SMN1; SMN2 | |
| SCHEMBL5469907 | 0.76 | HSD17B10 (0.61) | HSD17B10NPC1LMNANPSR1SMN1; SMN2 | |
| SCHEMBL1799846 | 0.76 | HSD17B10 (0.57) | HSD17B10NPC1LMNANPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544972-B1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER (US) | 2023-04-26 | — | — | EP | disclosed |
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | OPRK1, OPRD1, OPRM1 | HSD17B10 2705/4885NPC1 2458/4885LMNA 2841/4885 |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | OPRK1, OPRD1, OPRM1 | HSD17B10 2705/4885NPC1 2458/4885LMNA 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.